BIONOMICS RECEIVES $7.04M 2013 R&D TAX INCENTIVE

Bionomics Limited (ASX:BNO, ADR:BMICY) has received an Australian R&D tax incentive of $7.04 million after the recent lodgment of its FY2013 tax return. The incentive refund is in line with the estimate announced on 8 October.

Bionomics recently received confirmation that overseas expenditure on BNC101 and other programs within its pipeline totaling $17.42 million are eligible for the R&D tax incentive for at least three years commencing 1 July 2012.

This is in addition to a separate finding announced in January that covers BNC105 and BNC375 expenditure of $8.9 million for three years from 1 July 2011.

"Such a large injection of cash is important to Bionomics as we continue to progress a number of drug candidates along the pipeline including BNC101, which will enter the clinic for the first time in 2014," said Dr Deborah Rathjen, Bionomics' CEO and MD.

"It is pleasing to know we will be eligible for the incentive for all these programs in the year to June 2014 as well."

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited  Monsoon Communications  The Trout Group
Dr Deborah Rathjen  Rudi Michelson  Lauren Glaser
CEO & Managing Director  +613 9620 3333  +1 646 378 2972
+618 8354 6101 /  rudim@monsoon.com.au  lglaser@troutgroup.com
0418 160 425  drathjen@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule and antibody product development programs in the areas of cancer, anxiety, and memory loss. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.
Bionomics' discovery and development activities are driven by its four proprietary technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains “forward-looking” statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Ironwood Pharmaceuticals and Merck, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers’ markets, our failure to introduce new products or technologies in a timely manner, Ironwood’s decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.